Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

1.

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.

Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA.

Clin Gastroenterol Hepatol. 2010 Aug;8(8):655-9. doi: 10.1016/j.cgh.2010.04.023. Epub 2010 May 6.

PMID:
20451665
[PubMed - indexed for MEDLINE]
2.

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF.

Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. doi: 10.1016/j.cgh.2008.03.014.

PMID:
18550004
[PubMed - indexed for MEDLINE]
3.

Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.

[No authors listed]

Prescrire Int. 2009 Jun;18(101):108-10.

PMID:
19637418
[PubMed - indexed for MEDLINE]
4.

Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).

Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M; Swiss IBDnet and Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2012 Aug;18(8):1523-30. doi: 10.1002/ibd.21888. Epub 2011 Oct 10.

PMID:
21987429
[PubMed - indexed for MEDLINE]
5.

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.

Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, van Assche G, Rutgeerts P, Lémann M, Colombel JF.

Aliment Pharmacol Ther. 2010 Jan;31(1):92-101. doi: 10.1111/j.1365-2036.2009.04130.x. Epub .

PMID:
19709098
[PubMed - indexed for MEDLINE]
6.

Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease.

Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ, Loftus EV, Larson DW.

J Gastrointest Surg. 2010 Dec;14(12):1859-65; discussion 1865-6. doi: 10.1007/s11605-010-1341-5. Epub 2010 Sep 25.

PMID:
20872084
[PubMed - indexed for MEDLINE]
7.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
[PubMed - indexed for MEDLINE]
8.

Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.

Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators.

Clin Gastroenterol Hepatol. 2010 Jul;8(7):600-9. doi: 10.1016/j.cgh.2010.01.014. Epub 2010 Feb 1.

PMID:
20117244
[PubMed - indexed for MEDLINE]
9.

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

Peyrin-Biroulet L.

Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43. Review.

PMID:
20485259
[PubMed - indexed for MEDLINE]
10.

Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.

Rubin DT, Uluscu O, Sederman R.

Inflamm Bowel Dis. 2012 Dec;18(12):2225-31. doi: 10.1002/ibd.22925. Epub 2012 Feb 22.

PMID:
22359399
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet.

Inflamm Bowel Dis. 2010 Jun;16(6):933-8. doi: 10.1002/ibd.21127.

PMID:
20014021
[PubMed - indexed for MEDLINE]
12.

Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease.

Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN.

Inflamm Bowel Dis. 2013 Feb;19(2):309-15. doi: 10.1002/ibd.23026.

PMID:
22605668
[PubMed - indexed for MEDLINE]
13.

Certolizumab pegol for the management of Crohn's disease in adults.

Rivkin A.

Clin Ther. 2009 Jun;31(6):1158-76. doi: 10.1016/j.clinthera.2009.06.015. Review.

PMID:
19695385
[PubMed - indexed for MEDLINE]
14.

Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.

Absah I, Faubion WA Jr.

Inflamm Bowel Dis. 2012 Aug;18(8):1488-92. doi: 10.1002/ibd.21885. Epub 2011 Aug 31.

PMID:
21882301
[PubMed - indexed for MEDLINE]
15.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
[PubMed - indexed for MEDLINE]
16.

Practice patterns in the use of anti-tumor necrosis factor alpha agents in the management of Crohn's disease: a US national practice survey comparing experts and non-experts.

Swaminath A, Lebwohl B, Capiak KM, Present DH.

Dig Dis Sci. 2011 Apr;56(4):1160-4. doi: 10.1007/s10620-010-1530-9. Epub 2010 Dec 23.

PMID:
21181440
[PubMed - indexed for MEDLINE]
17.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
[PubMed - indexed for MEDLINE]
18.

[Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].

Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.

Przegl Lek. 2011;68(9):602-5. Polish.

PMID:
22335009
[PubMed - indexed for MEDLINE]
19.

How to improve the safety of biologic therapy in Crohn's disease.

Ferkolj I.

J Physiol Pharmacol. 2009 Dec;60 Suppl 7:67-70. Review.

PMID:
20388947
[PubMed - indexed for MEDLINE]
Free Article
20.

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE.

Clin Gastroenterol Hepatol. 2009 Aug;7(8):874-81. doi: 10.1016/j.cgh.2009.01.004. Epub 2009 Jan 24.

PMID:
19558997
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk